This distinction is critical, as misdiagnosing cMCADs patients with coexisting HαT could have serious consequences, given their increased risk of anaphylaxis and the availability of effective treatment, such as long-term venom immunotherapy. This evidence concerns the gene TMPRSS11D and anaphylaxis.